Description
This book celebrates the evolution of drug discovery and development. The authors highlight the tireless efforts of discovery and process chemists, and their roles in the advancement of drug discovery and development. The chapters highlight examples of emerging concepts, new developments and challenges arising in the discovery of new drug candidates and the development of new practical synthetic chemistry processes to produce these drug candidates on large scale. Ahmed F. Abdel-Magid received his Bachelor’s degree (1969) and Master’s degree (1973) from Cairo University and his PhD (1980) from Temple University. After postdoctoral appointments at the University of South Carolina and SmithKline Beckman Pharmaceuticals, he worked at Drexel University as Teaching/Research Associate (1985-1986) then as Adjunct Professor (1986-2006). He joined the Process Chemistry Department at Wyeth Laboratories as Senior Chemist (1986-1987), then moved to the Process Chemistry Group at Johnson & Johnson PRD (1987-2008) as a Senior Scientist and rose through the ranks to Senior Research Fellow. He joined Therachem Research Medilab in 2009 where he holds the title of Executive VP and Chief Scientific Officer. Jaan A. Pesti received his BS degree from Long Island University, Brooklyn, NY in 1976 and his Ph.D. in organic chemistry from Columbia University in 1981. Following postdoctoral research in synthetic organic chemistry at University of California, Berkeley from 1981-1983, he joined the staff of Dupont’s Medical Products Division in Wilmington, DE and Deepwater, NJ. He later transitioned to Dupont Merck Pharmaceuticals, Dupont Pharmaceuticals, and joined Bristol-Myers Squibb Pharmaceuticals in 2001. He retired from BMS in 2013 after 30 years of service, but has worked for NAL Pharma, Gelest Inc., and EnginZyme AB since that date. Rajappa Vaidyanathan obtained his Bachelor’s degree from Loyola College, Madras, and his Master’s from the Indian Institute of Technology, Madras. He completed his Ph.D. in 1998 from the University of California, Irvine. After a post-doctoral appointment at Eli Lilly and Company, he joined the Chemical Process R&D group of Pharmacia Corporation, Kalamazoo, MI, and subsequently Pfizer in Groton, CT. He is currently Group Director and Head of Chemical, Synthetic and Analytical Development at Bristol-Myers Squibb in Bangalore, India.
